Protara Therapeutics, Inc. (TARA)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$3.28−$0.0700 (−2.09%) on the dayAs of the close; data may be delayed.
TARA price, last 12 months
Key stats
- Previous close
- $3.35
- Open
- $3.35
- Day range
- $3.23 – $3.44
- 52-week range
- $3.23 – $7.82
- Volume
- 481.8K
- Avg volume (20 days)
- 876.5K
- Market cap
- $193.8M
Performance
1W−7.6%
1M−16.1%
3M−20.4%
6M−36.8%
YTD−38.5%
1Y−19.6%
vs S&P 500, 1Y−36.4 pts
Technicals and fundamentals
About Protara Therapeutics, Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $193.8M